Active Ingredient History
Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). Escitalopram, also known by the brand names Lexapro and Cipralex among others, is an antidepressant. The mechanism of antidepressant action of escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100-fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. LEXAPRO (escitalopram) is indicated for the treatment of major depressive disorder and generalized anxiety disorder . NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Pain (Phase 4)
Agoraphobia (Phase 4)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Amyloid beta-Peptides (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 3)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Anxiety, Separation (Phase 3)
Aphasia (Phase 2)
Arthritis, Rheumatoid (Phase 3)
Asthma (Phase 4)
Behavior, Addictive (Phase 2)
Bile Duct Neoplasms (Phase 3)
Bipolar Disorder (Phase 4)
Borderline Personality Disorder (Phase 2)
Brain Injuries, Traumatic (Phase 2)
Burning Mouth Syndrome (Phase 3)
Carcinoma (Phase 3)
Cocaine-Related Disorders (Phase 2/Phase 3)
Cognition Disorders (Phase 3)
Cognitive Dysfunction (Phase 2/Phase 3)
Colorectal Neoplasms (Phase 3)
Constipation (Phase 2/Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Dementia (Phase 4)
Depression (Phase 4)
Depression, Postpartum (Phase 4)
Depressive Disorder, Major (Phase 4)
Depressive Disorder, Treatment-Resistant (Phase 3)
Diabetes Mellitus (Phase 4)
Dyspepsia (Phase 3)
Dysthymic Disorder (Phase 4)
Epilepsy (Phase 4)
Epilepsy, Temporal Lobe (Phase 4)
Esophageal Neoplasms (Phase 3)
Facial Pain (Phase 4)
Fatigue (Phase 3)
Fear (Phase 4)
Fibromyalgia (Phase 3)
Gallbladder Neoplasms (Phase 3)
Gender Dysphoria (Phase 4)
Glioblastoma (Phase 2/Phase 3)
Glioma (Phase 2)
Healthy Volunteers (Phase 4)
Heart Failure (Phase 4)
Hepacivirus (Phase 1)
Hepatitis C (Phase 2/Phase 3)
Hepatitis C, Chronic (Phase 2)
HIV (Phase 4)
HIV Infections (Phase 3)
Hypercapnia (Phase 1)
Hypersensitivity (Phase 2)
Hypertension, Pulmonary (Phase 3)
Infertility, Male (Phase 2)
Internet Addiction Disorder (Phase 4)
Irritable Bowel Syndrome (Phase 4)
Kidney Failure, Chronic (Phase 2)
Liver Neoplasms (Phase 3)
Low Back Pain (Phase 4)
Lung Neoplasms (Phase 3)
Multiple Sclerosis (Phase 4)
Myocardial Ischemia (Phase 4)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neuronal Plasticity (Phase 4)
Night Eating Syndrome (Phase 3)
Obsessive Behavior (Phase 4)
Obsessive-Compulsive Disorder (Phase 4)
Opioid-Related Disorders (Phase 3)
Pain (Phase 4)
Pain, Postoperative (Phase 4)
Pancreatic Neoplasms (Phase 3)
Panic Disorder (Phase 4)
Parkinson Disease (Phase 3)
Phobia, Social (Phase 4)
Phobic Disorders (Phase 2/Phase 3)
Polycystic Ovary Syndrome (Phase 4)
Polyneuropathies (Phase 4)
Premature Ejaculation (Early Phase 1)
Premenstrual Syndrome (Phase 4)
Prostatic Neoplasms (Phase 2/Phase 3)
Psychiatry (Phase 2)
Psychomotor Agitation (Phase 4)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Respiratory Insufficiency (Phase 1)
Schizophrenia (Phase 4)
Selective Serotonin Reuptake Inhibitors (Phase 4)
Sinusitis (Phase 4)
Sleep Wake Disorders (Phase 4)
Somatoform Disorders (Phase 3)
Spinal Cord Injuries (Phase 1)
Stomach Diseases (Phase 2/Phase 3)
Stomach Neoplasms (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Phase 1)
Suicide, Attempted (Phase 2/Phase 3)
Treatment Outcome (Phase 3)
Urinary Bladder, Overactive (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
